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BACKGROUND: Small case series have reported successful live births after ovarian tissue cryopreservation and orthotopic transplantation,
demonstrating that it can be of value in increasing the chance of successful pregnancy after treatment for cancer and other fertility-impacting
diseases in adult women.
OBJECTIVE AND RATIONALE: This review is intended to set out the current clinical issues in the field of ovarian tissue cryopreserva-
tion, and elucidate the status of laboratory studies to address these.
SEARCH METHODS: We reviewed the English-language literature on ovarian tissue cryopreservation and in vitro maturation (IVM) of
ovarian follicles.
OUTCOMES: Ovarian tissue cryopreservation is increasingly used for fertility preservation and, whilst areas for development remain (opti-
mal patient selection, minimizing risk of contamination by malignant cells and IVM protocols), there are emerging data as to its efficacy. We
review the current status of ovarian tissue cryopreservation in girls and young women facing loss of fertility from treatment of cancer and
other serious diseases. Increasingly large cohort studies are reporting on success rates from ovarian tissue cryopreservation giving an indica-
tion of likely success rates. Patient selection is necessary to ensure the safety and effectiveness of this approach, especially in the very experi-
mental situation of its application to prepubertal girls. There are continuing developments in supporting follicle development in vitro.
LIMITATIONS, REASONS FOR CAUTION: The evidence base consists largely of case series and cohort studies, thus there is the possi-
bility of bias in key outcomes. In vitro development of human ovarian follicles remains some way from clinical application.
WIDER IMPLICATIONS OF THE FINDINGS: Ovarian tissue cryopreservation is becoming established as a valuable approach to the
preservation of fertility in women. Its application in prepubertal girls may be of particular value, as it offers the only approach in this patient
group. For both girls and young women, more accurate data are needed on the likelihood of successful childbirth after this procedure and the
factors that underpin successful application of this approach, which will lead to its more effective use.
STUDY FUNDING/COMPETING INTERESTS: The author’s work in this field is supported by Medical Research Grant (MRC) grants
G0901839 and MR/L00299X/1 and partially undertaken in the MRC Centre for Reproductive Health which is funded by MRC Centre
grant MR/N022556/1. The authors declare that there is no conflict of interest that could prejudice the impartiality of the present
research.
Key words: cryopreservation / gonadotoxicity / fertility preservation / tissue culture / ivm: artificial ovary
© The Author 2017. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse,
distribution, and reproduction in any medium, provided the original work is properly cited.
Introduction
Advances in treatment of many cancers with consequent dramatic
improvements in long-term survival (Miller et al., 2016) have led to
increasing awareness of the issues in what is sometimes termed ‘sur-
vivorship’ to encompass the wide range of medical and social issues
faced by cancer survivors. Amongst medical issues, the potential
effects on fertility are an important concern of young women facing
therapy for cancer and other conditions treated with similar che-
motherapeutic regimens (Peate et al., 2011), and the field of fertility
preservation has grown rapidly over the last two decades (Ataman
et al., 2016). The most common cancers in girls and young women are
those of the breast, cervix, central nervous system, leukaemias and
lymphomas. Treatment of all these conditions may compromise fertil-
ity in girls and young women as a result of the surgery, chemotherapy
and radiotherapy required for treatment.
Ovarian tissue cryopreservation is one of several options available
for female fertility preservation, together with oocyte and embryo
cryopreservation (Loren et al., 2013; Anderson et al., 2015) (Fig. 1).
Other approaches include administration of agents that might pro-
tect the ovary, such as GnRH analogues (Lambertini et al., 2015),
and surgical transposition of the ovary to reduce the radiation dose
(Gubbala et al., 2014). This review will focus on ovarian tissue cryo-
preservation and address some of the outstanding issues involved
in the development of this approach, including issues surrounding
patient selection, the evidence for its efficacy and the current status
of attempts to circumvent one of the significant issues with this tech-
nique, i.e. the potential presence of malignant cells contaminating
the cryopreserved tissue.
The potential value of cryopreservation of ovarian tissue was first
demonstrated in a series of experiments in the sheep where autografts
of cryopreserved ovarian cortex were sutured on to the ovarian ped-
icle, with subsequent restoration of ovarian cyclicity and natural con-
ception (Baird et al., 1999). These key experiments demonstrated the
potential of this approach for clinical application but the detailed histo-
logical analysis that accompanied them also showed one of the major
issues, which is that the majority of primordial follicles in the cryopre-
served tissues do not survive. This is thought to be due to ischaemia
prior to revascularization of the graft rather than direct cryo-damage
and there is, as yet, no clear way of markedly improving this. The
advent of vitrification, which has transformed the cryopreservation of
mature oocytes, may offer some advantages in reducing the cryo-
damage that does occur (Ting et al., 2011; Amorim et al., 2012; Zhou
et al., 2016), and indeed has been successfully used clinically in this
context, but it does not address the problem of revascularization. One
approach to that problem is the cryopreservation of the whole ovary
with subsequent vascular re-anastomosis, and whilst there have been
developments towards successful use of this approach in animal mod-
els (Campbell et al., 2014), it remains some way from clinical practice.
Search Methods
We reviewed the English-language literature on ovarian tissue cryo-
preservation and IVM of ovarian follicles using conventional search
methods. This was supplemented with searching cited publications in
identified reports, and personal contacts with several key researchers.
When and for whom is ovarian
tissue cryopreservation
appropriate?
This question raises much broader issues than strictly medical ones,
and includes assessment of risk of loss of fertility, patient autonomy,
decision-making at a time of stress and potential information overload,
and cost (either to the patient or the health service). This can, in part,
be perceived as the need to strike a balance between offering fertility
preservation to all at risk, or only to those with a clear need, i.e. at
high risk. Part of the evidence base relevant to this is analysis of which
cancer treatments clearly do or do not impact on female fertility. The
most detailed information on this is derived from the US Childhood
Cancer Survivor Study (CCSS) which has for many years published
analyses of reproductive outcomes in a cohort of cancer survivors
using their siblings as the control group (Chemaitilly et al., 2006;
Signorello et al., 2006; Green et al., 2009). A recent report from this
study analysed chemotherapy exposures in relation to the prevalence
of pregnancy and live birth in women who had been exposed to
chemotherapy: females who had received cranial or pelvic radiother-
apy were excluded from this analysis (Chow et al., 2016). The overall
hazard ratio for pregnancy was 0.87 (95% CI: 0.81–0.94) compared
with the control group of their siblings, demonstrating that most
women who have had chemotherapy for cancer treatment in
WHATDOES THIS MEAN FOR PATIENTS?
Freezing part of an ovary before treatment for cancer and other diseases that might lower fertility can provide women with a better chance of
having a baby once they have recovered. Approximately 100 successful live births have occurred after replacing this ovarian tissue.
The procedure of freezing ovarian tissue (cryopreservation) and later transplanting it back to the body raises a number of important clinical
questions. This review identified what these main issues are and what studies have been, and still need to be, carried out.
Increasing the use of ovarian cryopreservation is providing results on the likely successful birth rates but more information is required. It may
be more suitable for some women than others and careful patient selection will be needed, especially to get a more accurate prediction of the
risk of loss of fertility to the individual patient. Researchers are also working on better ways to support growth of follicles (where immature eggs,
or oocytes, are found) in the laboratory, for future use in the IVF clinic.
Studies show that freezing of ovarian tissue for later transplantation is a major advance for fertility preservation. However, it is not suitable for
all patients as there may be concerns about transplanting cancer cells into disease-free patients. The key areas for further study are optimal
patient selection, minimizing risk of contamination by cancer cells and improving laboratory protocols for oocyte maturation.
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childhood will be able to have children. Detailed analysis of the particu-
lar agents involved identified that alkylating agents were only asso-
ciated with a decrease in the risk of pregnancy and live birth at the
highest doses. A similar result was reported from a recent analysis of
survivors of Hodgkin lymphoma in childhood and adolescence from
Germany, in which the overall chance of parenthood of Hodgkin
lymphoma survivors was very similar to that of the German population
(Bramswig et al., 2015). They showed that procarbazine in cumulative
doses up to 11 400 mg/m2 and cyclophosphamide in cumulative doses
up to 6000 mg/m2 had no significant or only minor effects on parent-
hood. The chance of parenthood was however significantly reduced in
survivors receiving pelvic radiation. These studies also highlight that it
is the treatment rather than the diagnosis that determines the risk, and
also that the majority of young cancer survivors will go on to have the
opportunity to have a family.
This information underpins the other aspect of the argument,
whether this approach should be primarily aimed at those with a clear
need, i.e. where a significant risk of loss of fertility is predicted based
on the planned treatment. Ovarian tissue cryopreservation for restor-
ation of fertility remains widely regarded as an experimental procedure
(Loren et al., 2013), although increasing experience with it has led to it
becoming established practise in Israel (Meirow et al., 2016). In our
view, patients having ovarian tissue cryopreservation should be coun-
selled and have their data collected in a research context, to improve
the evidence base underpinning this approach. This is particularly
important for children and younger adolescents where proxy consent
from parents and carers is often the norm (Wallace et al., 2016). It
remains important to avoid unnecessary intervention or procedures of
uncertain benefit in unwell children at a time of extreme stress to the
patient and their parents and carers. To provide a structure for discus-
sions surrounding whether or not to proceed with ovarian tissue cryo-
preservation, we have developed a risk assessment tool, dividing the
key issues into those intrinsic to the patient, and those extrinsic
(Table I)(Wallace et al., 2012).
The intrinsic factors include whether the patient is well enough to
have the necessary laparoscopic surgery to remove ovarian tissue. This
should include assessment of coagulation disorders, infection risk, issues
regarding the risk of anaesthesia and the potential risk of contamination
of ovarian tissue by malignant disease (the latter is discussed more fully
below). Issues regarding informed consent have been mentioned above.
Whilst there is no theoretical lower age limit for the potential value of
ovarian tissue cryopreservation, the decline in the ovarian reserve
(Wallace and Kelsey, 2010), and in natural fertility in the later 30s and
the consequent chances of success of the procedure in terms of restor-
ing fertility should be clearly discussed. Assessment of the ovarian
reserve using biomarkers such as anti-Müllerian hormone (AMH) or
antral follicle count are routinely performed prior to assisted repro-
duction to predict the patient’s response (Iliodromiti et al., 2014).
Many studies have shown a reduction in these biomarkers after cancer
treatments indicating their potential to quantify ovarian toxicity and
distinguish between the effects of different regimens (Bath et al., 2003;
Lutchman Singh et al., 2007; Lie Fong et al., 2008; Decanter et al.,
2010). Pretreatment levels of AMH have also been shown to predict
the risk of amenorrhoea in women subsequently treated with chemo-
therapy for breast cancer (Anderson and Cameron, 2011; Su et al.,
2014), substantiating the hypothesis that women with a higher ovarian
reserve pretreatment are more likely to have ongoing ovarian function
thereafter. Such studies have not been performed with fertility as an
outcome but this approach does seem to have some promise to indi-
vidualize more accurately the risk of specific therapies. It would seem
likely that these biomarkers could be used to give some prediction of
remaining postchemotherapy ovarian function and reproductive life-
span. Similar analyses have been performed in healthy women, but
accurate prediction of remaining reproductive lifespan seems only
poorly predicted by, for example, AMH, except at particularly low
levels in younger women (van Disseldorp et al., 2008; Tehrani et al.,
2013). Even then, sporadic ovulation in young women will allow some
to conceive. The limited value of these markers for prediction reflects
our poor understanding of ovarian compensation after such damage,
and this is an area where research could have a marked impact on
clinical practice.
The key extrinsic factor is the nature of the predicted treatment and,
as mentioned above, the key risk factors are the administration of whole
body, pelvic (or abdominopelvic in children) radiotherapy and high-dose
alkylating agents. The patient’s age is probably the most important deter-
minant of how damaging these therapies are, as reflected in the dramatic
increase in risk of amenorrhoea after chemotherapy in women treated
for breast cancer with older age at treatment (Petrek et al., 2006).
However, a significant problem is that even therapies that have low risk,
such as the commonly administered ABVD regimen for early stage
Hodgkin lymphoma, may have some impact on ovarian function (poten-
tially in those with lower pretreatment ovarian reserve) as women trea-
ted with this regimen have recently been shown to have a reduced
oocyte yield when oocyte collection for cryopreservation is subsequently
Figure 1 Ovarian tissue cryopreservation within the wider context
of fertility preservation for girls and women. Cryo: cryopreservation.
Adapted from Anderson et al. (2015).
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performed following relapse of the disease (Sonigo et al., 2016), although
no effect on risk of early menopause (before the age of 40 years) has
been reported (Swerdlow et al., 2014). This also highlights that whereas
initial therapy for the primary malignancy may carry a low risk of prema-
ture ovarian insufficiency (POI) and infertility, treatment may change
depending on initial response (e.g. in lymphoma: Barrington et al., 2016)
and regimens used for relapse will generally carry a high risk. Ovarian tis-
sue cryopreservation and restoration of fertility potential is likely to be
more effective if those patients had undergone fertility preservation pro-
cedures at the time of initial diagnosis. Treatment protocols to minimize
the risk of recurrence in combination with reducing general, including
gonadal, toxicity are continually evolving.
The potential value of careful prediction of risk of treatment to ovar-
ian function has been supported by an analysis of ovarian function in a
population of children and young adults aged up to 18 years, some of
whom were offered ovarian tissue cryopreservation (Wallace et al.,
2014). This showed that those who met the criteria and were there-
fore offered ovarian tissue cryopreservation had a substantial risk of
POI during the course of the period of follow-up, of 35% over the
15 year follow-up period. This contrasted with a prevalence of only
1% (1 individual in a cohort of 141) in those not offered ovarian tissue
cryopreservation giving a hazard ratio of 56.8 (95% CI: 6.2–521.6) at
10 years follow-up. The young age of the population studied precluded
the use of fertility as the key outcome but this clearly shows the poten-
tial for focussed patient selection. In contrast, in a relatively unselected
population of women who underwent pre-chemotherapy unilateral
oophorectomy for fertility preservation, follow-up at a mean of 58
months showed a prevalence of POI of 9% in women with breast can-
cer, and 18% in those with lymphoma, but 87% of those with leukae-
mia, reflecting the widespread use of bone marrow transplantation in
that group (Schmidt et al., 2013). Overall, 41 of the 57 women in the
group who had tried to conceive had been successful, i.e. a retained
fertility rate of 72%. Whilst the issues surrounding the provision of all
aspects of fertility preservation require a much more complete evi-
dence base than is currently available, it seems clear that one aspect
that should be addressed is the need for more accurate identification
of those who are very likely to retain their fertility after their cancer
treatment, which will guide both patients and medical services in the
provision of this treatment option.
How effective is ovarian tissue
cryopreservation?
The first successful pregnancy after replacement of cryopreserved ovar-
ian tissue was reported in 2004 (Donnez et al., 2004) and at present
there are ~100 babies born following this procedure, although this num-
ber is increasing all the time. An analysis of 60 tissue replacements car-
ried out in Belgium, Denmark and Spain demonstrated that over 90% of
women showed some evidence of ovarian activity, first seen a median of
4 months after transplantation (Donnez et al., 2013). Eighteen per cent
of these women achieved a pregnancy, the majority after natural con-
ception, and 12 live births were recorded from 6 women. An updated
analysis including additional centres (total 111 women) indicated a 29%
pregnancy rate. An analysis of 41 transplantations in Denmark showed
that 31% of those wishing to conceive had a successful pregnancy
(Jensen et al., 2015): 100 replacements have now been performed there
(C.Y. Andersen, personal report). A recent report has presented data
on 95 orthotopic cryopreserved ovarian tissue transplantations in 74
women in the FertiProtekt Network (Van der Ven et al., 2016). These
women had an average age of 30 years at cryopreservation and 34 years
at transplantation, with the two most common diagnoses being breast
cancer and Hodgkin lymphoma. Amongst those undergoing their first
transplantation who had clear evidence of POI at the time of transplant-
ation, 62.5% showed evidence of ovarian activity 1 year after transplant-
ation, and 27.5% achieved a pregnancy with delivery in 22.5%. These
case series provide, at present, the best estimate of the likely success of
this approach, although no doubt additional pregnancies will be
achieved, increasing the overall success rate. Indeed, there are case
reports of individual women having up to three successful pregnancies
after ovarian tissue replacement, with graft function lasting up to 10
years (Jensen et al., 2015). Calculation of success rate is however com-
plicated by a range of issues including that some transplantations are not
being performed to restore fertility but for endocrine reasons, and that
some women have some residual ovarian activity at the time of trans-
plantation (Andersen, 2015).
The majority of these pregnancies were after natural conception, and
the potential for this is one of the key positive aspects of ovarian tissue
cryopreservation compared with oocyte or embryo cryopreservation.
A more aggressive approach with repeated cycles of ovarian stimulation
to either achieve pregnancy with fresh embryo replacement (Meirow
et al., 2016) or, indeed, to bank cryopreserved embryos whilst the
ovarian graft remains functional (Oktay et al., 2016) has also been
reported. In one series of 20 women, some of whom had previously
received chemotherapy for leukaemia or lymphoma, 32% had a baby
after up to 11 cycles of IVF (Meirow et al., 2016). However, in a total of
56 IVF cycles, a total of only 84 oocytes were obtained, but a fertiliza-
tion rate of 58% was achieved with embryo transfer in 68% of cycles.
In addition to the potential for natural conception, endogenous hor-
mone production by the graft is also a key benefit of this approach. The
great majority of ovarian replacements showed evidence of hormonal
activity, although for a variable duration, occasionally up to several
years. It is unclear at present what factors predict the duration of
the graft, and how much can be related to surgical technique at
Table I Intrinsic and extrinsic factors that should be
taken into account when considering fertility
preservation strategies for girls and young women
undergoing treatment.
Intrinsic factors
Health status of the patient
Psycho-social factors
Consent (patient/parent)
Assessment of pubertal status
Assessment of ovarian reserve
Extrinsic factors
Nature of predicted treatment (high/medium/low/uncertain risk)
Time available
Expertise/technical options available
Reprinted with permissions from Anderson et al. (2015).
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replacement compared with the intrinsic functional potential of the tis-
sue. Related to this, replacement has also been proposed as a method
for inducing puberty (Poirot et al., 2012; Ernst et al., 2013). This, how-
ever, is controversial for a number of reasons (Anderson et al., 2013).
These include that it results in rapid escalation of oestrogen levels to
adult concentrations, in contradiction to the established principles of
pubertal induction with slow progression and escalation of oestrogen
dose. Additionally, the early onset of ovulatory cycles will expose the
patient to progesterone earlier than would occur during normal
puberty, which may impact on normal breast development. The tissue
also contains a finite number of oocytes, thus this could be argued to
be a wasteful use of this scarce resource. There is also the potential risk
of malignant contamination, discussed more fully below. However,
there is also clear value to women from endogenous and physiological
hormone production. The adverse health effects of POI are increasingly
recognized and whilst it is very likely that many of these are reduced by
appropriate exogenous hormone replacement, there is a paucity of
robust evidence regarding the risks and benefits of HRT in women with
POI (Langrish et al., 2009; Crofton et al., 2010), with much of it being
extrapolated from women taking HRT after a physiological menopause
(ESHRE Guideline Group on POI et al., 2016). Replacement of cryopre-
served ovarian tissue purely for hormone production rather than fertil-
ity has been proposed (Andersen and Kristensen, 2015). This may well
be appropriate for some women who have completed their family or
no longer wish to pursue fertility, taking into account the risk of malig-
nant contamination, the uncertain duration of function of replaced
ovarian tissue, and issues surrounding risks and benefits of hormone
‘replacement’ beyond the age of natural menopause.
The risk of malignant
contamination
The storage of ovarian tissue before cancer treatment is started carries
with it the risk that the tissue will contain malignant cells, which will sur-
vive cryopreservation and could potentially be transplanted back into
the patient with the risk of recurrence of the malignancy. A range of
methods specific to the diagnosis can be used to detect malignant con-
tamination, including immunohistochemistry and molecular analysis,
and a sample of tissue should be sent for such analysis at the time it is
stored. These tests are all, however, destructive, and therefore cannot
be applied to the actual pieces of tissue that will be replaced in the
patient. In general, it is considered that where there is no evidence of
metastatic disease of solid cancers, then the risk of ovarian contamin-
ation is low. However, for leukaemias before treatment has started
there is a high risk that circulating malignant cells will be present in the
ovary, and this has been confirmed in a number of studies specifically
investigating this (Greve et al., 2012; Dolmans et al., 2013; Rosendahl
et al., 2013). This also confirms the potential of these tests to identify
malignant contamination although there may be issues of sensitivity to
pick up minimal residual disease, which will be expected to improve
with time. A high level of vigilance is required to detect contamination
even when the diagnosis and staging tests indicate a low risk. In our
own series of patients, we have identified a case of ovarian contamin-
ation with Ewing’s sarcoma that had arisen in a thoracic (T7) vertebra
and conventional staging showed no evidence of metastatic disease
(Fig. 2). The identification of this contamination will, of course, preclude
replacement of the tissue and alternative approaches to the restor-
ation of fertility in such patients are required. These are discussed
below. The application of ovarian tissue cryopreservation in patients
with leukaemia remains controversial because of this risk of contamin-
ation. It has been proposed that ovarian tissue can be taken following
initial courses of chemotherapy, potentially sufficient to reduce the
risk of cryopreservation of circulating malignant cells but without
excessively compromising ovarian function (Greve et al., 2012).
Whilst successful cases have been reported (Meirow et al., 2016), the
benefits and risks of this approach have yet to be clearly quantified
and undertaking ovarian tissue cryopreservation in these patients
remains contentious.
Developing methodologies
to optimize the potential
of cryopreserved tissue
Whilst reimplantation of ovarian tissue has been a major advance for
fertility preservation, it is not suitable for all patients as there may be
concerns about transplanting malignant cells into disease-free patients.
With these concerns in mind, a great deal of research has focused on
first, isolating follicles from tissue at specific stages of development
either before or after cryopreservation, removing any contaminating
cells and recombining the follicles within a supportive matrix to form
an ‘artificial ovary’ for subsequent reimplantation or in vitro develop-
ment, and second, developing oocytes from cryopreserved tissue
completely in vitro.
Making an artificial ovary
The aim of developing an ‘artificial ovary’ is to produce a structure that
would be free of any potential malignant cells and contain healthy
immature follicles (and stromal cells). Groups working in this area have
focused on isolation methods and in developing matrices to support
isolated follicles (Skory et al., 2015; Paulini et al., 2016). Developing the
optimal matrix to support follicle/oocyte development has been slow
but some advances have been made. The optimal matrix needs to sup-
port growth, development and recovery of human ovarian follicles as
well as control rigidity. Bioengineering has led to the development of
many materials to support follicle development (Shea et al., 2014).
Alginate has given positive results with mouse and human follicles (Yin
et al., 2016) and fibrin has also been demonstrated to be a viable
material to support isolated murine primordial follicles after transplant-
ation (Kniazeva et al., 2015). Decellularized ovary has been used to sup-
port the growth and development of mouse follicles (Laronda et al.,
2015). Recent work with isolated preantral human follicles has demon-
strated that a matrix formed by combining fibrin with fibrinogen and
thrombin improves the health and development of the encapsulated
follicles (Paulini et al., 2016). Work in this area is promising but there is
still much to be tested before an ‘artificial’ ovary could reach the clinic.
The avoidance of a transplantation procedure would be preferred
for some patients. To obtain fully grown competent oocytes from
cryopreserved tissue without a transplantation step would require the
immature oocytes to be grown completely ex vivo.
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Oocyte growth and development
in vitro using cryopreserved
tissue
Growth in vitro from the most immature oocytes (primordial stages)
with subsequent IVF and production of live young has only been
achieved in mouse (Eppig and O’Brien, 1996; O’Brien et al., 2003). The
complete process of murine oogenesis from the primordial germ cell
stage to the production of developmentally competent oocytes can be
recapitulated in vitro (Morohaku et al., 2016) and the resultant offspring
have been shown to be healthy. Whilst there are major differences
between human and mouse oocyte development, the mouse work
provides proof of concept that complete oocyte development can be
achieved in vitro and has driven the development of culture systems that
could be applied to other species, particularly human. Advances in cul-
turing follicles from humans, non-human primates and domestic species
have been made, bringing the prospect of achieving an in vitro system
that supports complete human oocyte development closer (Smitz
et al., 2010; Telfer and Zelinski, 2013; Xiao et al., 2015).
Several culture systems have been developed that have been opti-
mized for a range of different animal models (Smitz et al., 2010; Telfer
and McLaughlin, 2012; Telfer and Zelinski, 2013). Whilst some are more
advanced than others, there is not a single system that has been fully opti-
mized to support the complete in vitro growth and maturation of human
follicles and oocytes. All of the published systems have strengths and
weaknesses that may be usefully exploited to meet the challenges of
human follicle culture but there is agreement that to achieve complete
in vitro growth, a dynamic culture system is required to support the three
main transition steps in oocyte/follicle development, i.e. growth activa-
tion, ongoing culture of isolated follicles and final oocyte maturation.
In vitro activation of primordial
follicles
The regulation of follicle activation involves a combination of inhibitory,
stimulatory and maintenance factors (Nelson et al., 2013; Hsueh et al.,
2015). Work using knockout mouse models has highlighted the
importance of the phosphatidylinositol-3′-kinase (PI3K-AKT) signalling
pathway within the oocyte in regulating follicle activation (Reddy et al.,
2008). Using pharmacological inhibitors of phosphatase and tensin
homologue in vitro leads to increased activation of human primordial
follicles (Li et al., 2010; McLaughlin et al., 2014), whereas treatment
with rapamycin (an inhibitor of mammalian target of rapamycin com-
plex 1: mTORC) results in decreased activation (McLaughlin et al.,
2011). A human live birth has been reported following the treatment
of ovarian tissue for 48 h in vitro with bpV(HOpic) and 740YP, an Akt
stimulant, followed by replacement and IVF (Kawamura et al., 2013).
This is an extremely encouraging development but needs to be treated
with caution as similar inhibitors in vitro, whilst increasing activation of
500µM 200µM
Figure 2 Biopsy of ovary from a girl with Ewing’s sarcoma in a verte-
bra. A 12-year-old with Ewing’s sarcoma localized to the T7 vertebra
and no evidence of metastatic disease underwent ovarian biopsy for
fertility preservation. A biopsy sent for pathological examination
showed presumed malignant contamination, with CD99 positive cells
present consistent with metastatic Ewing’s sarcoma. Left panel, solid
arrow indicates area of CD99 positive cells in a haematoxylin and eosin
stained section, open arrow indicates primordial follicles in cortex of
ovary. Right panel: CD99 (brown stain) immunohistochemistry result.
Figure 3 Multistep culture system for activation of human primordial follicles and subsequent follicle/oocyte development. Primordial follicles can
be activated or held dormant within ovarian cortical tissue (a). Once activated preantral stages can be isolated (b), they are grown individually to antral
stages (c). These can be further grown, for example, within an alginate bead (d) to obtain fully grown oocytes (e), then competence to undergo matur-
ation and fertilization is tested.
6 Anderson et al.
primordial follicles, result in poor quality oocytes at later stages
(McLaughlin et al., 2014).
Isolation and culture of growing
follicles to achieve oocyte
growth and development
Once follicles have reached the multi-laminar preantral stage of devel-
opment, there are several culture systems that support further
growth. Placing preantral follicles in v-shaped micro-well plates allows
maintenance of three-dimensional follicular architecture in vitro whilst
promoting growth and differentiation of human follicles (Telfer et al.,
2008; Anderson et al., 2014; McLaughlin et al., 2014) with antral form-
ation occurring within 10 days. Follicle encapsulation in alginate hydro-
gels has also been used to support secondary human (Xu et al., 2009;
Xiao et al., 2015) and rhesus monkey (Ting et al., 2011) follicle growth
in vitro. Alginate encapsulation is believed to mimic the extracellular
matrix in vivo in terms of its ability to facilitate molecular exchange
between the follicle and the culture medium, and whilst its flexibility
can accommodate cell proliferation, its rigidity prevents dissociation of
the follicular unit. The progression of human follicles following isolation
from the cortex is remarkable. In the presence of FSH, enzymatically
isolated secondary human follicles can differentiate, become steroido-
genically active and complete oocyte growth in 30 days (Xu et al.,
2009) and have been shown to be capable of meiotic maturation
(Xiao et al., 2015).
Aspiration andmaturation
of oocyte cumulus complexes
The final goal of an in vitro system is to produce oocytes that can be
fertilized and produce developmentally normal embryos. In order to
achieve this, in vitro grown human oocytes need to be meiotically
matured in vitro and several groups have made important steps
towards this for clinical use over the last two decades (Alak et al.,
1998; Cha and Chian, 1998; Mikkelsen et al., 1999; Cavilla et al., 2008;
Chian et al., 2013). It is widely accepted that whilst 40–80% of imma-
ture human oocytes can successfully complete IVM and fertilization,
the rate of maturation of immature oocytes is still well below that of
oocytes harvested from stimulated ovaries, indicating that the proto-
cols are suboptimal or many of the harvested oocytes are intrinsically
unable to undergo maturation (Chang et al., 2014).
The challenge in developing a complete in vitro growth system is to
combine each of these stages to produce a multistep system that sup-
ports the complete process of oocyte development (Fig. 3).
Conclusion
Preservation of fertility in girls and young women with cancer who are at
risk of loss of fertility remains an important priority to improve their long-
term health and well-being. Oocyte and embryo cryopreservation are
established but in most countries in the world, ovarian tissue cryopreser-
vation remains experimental, particularly in younger adolescents and pre-
pubertal girls. Cryopreservation of ovarian cortical tissue with later
replacement has now resulted in at least 100 live births but requires an
additional invasive procedure at a time of emotional distress and uncer-
tainty, and there is an uncertain risk of tissue contamination in haemato-
logical and other malignancies. In vitro growth and maturation of
immature ovarian follicles is developing but further research is required
before it can be used for clinical benefit. Girls and young women having
ovarian tissue cryopreservation should be counselled and have their data
collected in a research context, to improve the evidence base underpin-
ning this approach. This field requires more basic and clinical research to
provide accurate information for patients and their medical teams and to
promote the development of ovarian cryopreservation as an effective
and cost-efficient treatment option for female fertility preservation.
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